OBM Hepatology and Gastroenterology

Free Publication in 2017

OBM Hepatology and Gastroenterology Editorial Office

2000 Auburn Drive, One Chagrin Highlands

Suite 200, Beachwood, OH 44122

USA

Tel.:  +1-216-370-7293

Fax:  +1-216-378-7505

E-Mail: hepat.gastroen@obm-pc.com

Current issue: 2017 
Editorial

Response-Guided Treatment with an Ultrarapid Virological Response Creates the Future of Interferon-Free Treatment against Hepatitis C

Tatsuo Kanda 1,* , Osamu Yokosuka 2 

  1. Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan
  2. Japan Community Healthcare Organization (JCHO), Funabashi Central Hospital, 6-13-10 Kaijin, Funabashi 273-8556, Japan

Correspondence: Tatsuo Kanda  .

Received: January 22, 2017 | Accepted: January 23, 2017 | Published: February 4, 2017

OBM Hepatology and Gastroenterology 2017, Volume 1, Issue 1, doi:10.21926/obm.hg.1701002

Recommended citation: Kanda T, Yokosuka O. Response-Guided Treatment with an Ultrarapid Virological Response Creates the Future of Interferon-Free Treatment against Hepatitis C. OBM Hepatol Gastroenterol 2017;1(1):002; doi:10.21926/obm.hg.1701002.

© 2017 by the authors. This is an open access article distributed under the conditions of the Creative Commons by Attribution License, which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is correctly cited.

Lau, et al. [1] reported the results of a phase 2, open-label, proof-of-concept study of 3-week response-guided direct-acting antiviral therapy for chronic hepatitis C genotype 1b patients. Rates of sustained virological response at 12 weeks (SVR12) after completion of therapy of three treatment groups (sofosbuvir, ledipasvir and asunaprevir; sofosbuvir, daclatasvir and simeprevir; or sofosbuvir, daclatasvir and asunaprevir) who achieved an ultrarapid virological response (URVR, plasma HCV RNA < 500 IU/mL by day 2, measured by COBAS TaqMan HCV test, version 2.0) were 100% for all three groups, although patients with URVR received only 3 weeks of therapy.

The results of this trial involving patients with a mean age of 41, 40 and 31 years and fibrosis stage F0-F1 of 67%, 67% and 100%, respectively, were excellent [1]. The results of the trials involving patients with HCV genotype 3 infection, advanced fibrosis and/or elderly patients would have been even more interesting if the authors had emphasized the factors associated with URVR in “difficult-to-treat” patients.

HCV genotype 3 infection is the most “difficult-to-treat” HCV genotype by interferon-free regimen worldwide [2]. SVR12 rates of patients with advanced fibrosis seem worse than those of patients with non-advanced fibrosis [3,4]. The older the patients are, the more medicines they need for their comorbid disorders. Interferon-free regimens against patients with HCV have shortened treatment duration, achieved more effective treatment results, and lessened adverse events. In our hospital, situated in an urban area of Japan, the proportions of patients aged 60 years or older with HCV genotypes 1 and 2 infection are 77% and 60%, respectively (unpublished data). Some of these patients have several comorbid disorders, making it difficult to even use a combination of two direct-acting antivirals (DAAs) against HCV, due to drug-drug interaction and others. Of course, it is preferable for older patients to have shorter treatment durations, and they would benefit from incurring less adverse events, but three or more of DAAs may be needed to obtain a better treatment response.

In any events, the results reported by Lau et al. [1] are wonderful. In addition, they also reported that URVR is very important marker for predicting SVR12 in 3 weeks with combinations of three drugs. Their study may be preliminary, but response-guided interferon-free treatment may pave the way through shortening the duration of treatment. The precision medicine initiative [5] may yet prove to be true.

Acknowledgements

This work was partly supported by the grants from the Japan Agency for Medical Research and Development.

Competing Interests

TK has received lecture fees from Chugai Pharmaceutical, MSD, Daiichi-Sankyo, Bristol-Myers Squibb, Gilead Sciences and AbbVie, and a research grant from Chugai Pharmaceutical, MSD, Sysmex, Tsumura and AbbVie.

References

  1. Lau G, Benhamou Y, Chen G, Li J, Shao Q, Ji D, et al. Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study. Lancet Gastroenterol Hepatol. 2016;1:97-104. DOI:10.1016/S2468-1253(16)30015-2. [CrossRef]
  2. Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, et al. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med. 2015;373:2608-17. DOI:10.1056/NEJMoa1512612. [CrossRef]
  3. Curry MP, O'Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, et al. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med. 2015;373:2618-28. DOI:10.1056/NEJMoa1512614. [CrossRef] [PubMed]
  4. Kanda T. Interferon-free treatment for HCV-infected patients with decompensated cirrhosis. Hepatol Int. 2017;11:38-44. DOI:10.1007/s12072-016-9749-y. [PubMed]
  5. The Whitehouse President Barack Obama. Accessed on 2017 January 22. Available from: https://www.whitehouse.gov/precision-medicine.